PRVB - Provention Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Provention Bio, Inc.

PO Box 666
Oldwick, NJ 08858
United States

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Ashleigh Palmer B.Sc., M.B.A.Co-Founder, Pres, CEO & Director583.5kN/A1963
Mr. Francisco Leon M.D., Ph.D.Co-Founder & Chief Scientific Officer564.5kN/A1972
Mr. Andrew T. DrechslerChief Financial Officer499kN/A1972
Dr. Eleanor L. RamosChief Medical Officer & COO534.62kN/A1956
Dr. Sherron KellSr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-300, an anti-TLR3 mAb, which is in Phase Ib clinical trial for the treatment of ulcerative colitis; PRV-3279, which is in phase Ib/IIa for the treatment of lupus; PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D; and PRV-015, which is in phase IIb for the treatment of gluten-free diet non-responding celiac disease. The company has a licensing and co-development agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.

Corporate Governance

Provention Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.